FDA issues concerns about optimal baricitinib doses for the treatment of moderate-to-severe rheumatoid arthritis and delays drug approval

    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.

Related Topics

    loading  Loading Related Articles